Limited launch expected for JenaValve's Trilogy System ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

The FDA has approved the Trilogy Transcatheter Heart Valve System for treating patients with symptomatic severe aortic ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...

Approval marks a historic milestone for Americans living with ssAR who are at high risk for surgery and previously had no dedicated transcatheter treatment option ...

Sports cardiology has emerged as a distinct subspecialty at the intersection of preventive cardiology and athlete care. While ...

With its FDA approval, JenaValve intends to commence launch activity for the Trilogy System immediately with participating ...

The Lancelot technology delivers enhanced hemodynamics through the integration of precision laser cutting and after ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...

I'm a 79-year-old female.

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.